Paul F. Lizzul - Jun 23, 2022 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role: Chief Medical Officer
Signature: /s/ Eric Loumeau, Attorney-in-Fact
Stock symbol: ANAB
Transactions as of: Jun 23, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/27/2022, 07:03 PM
Previous filing: Feb 14, 2022
Next filing: Sep 16, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANAB	Stock Option (right to buy)	Award	$0	+10K		$0.00	10K	Jun 23, 2022	Common Stock	10K	$29.70	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 10, 2021, the reporting person was granted a performance-based option to purchase 10,000 shares of the Issuer's common stock, subject to the achievement of certain corporate performance criteria and the reporting person's continued service to the Issuer upon achievement thereof. The performance criteria were achieved on the date in Column 3, resulting in the vesting of the entire award.
F2	In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 205,000 shares of common stock, which options vest according to their terms, and (ii) 1,751 shares of common stock held directly.

Content

On February 10, 2021, the reporting person was granted a performance-based option to purchase 10,000 shares of the Issuer's common stock, subject to the achievement of certain corporate performance criteria and the reporting person's continued service to the Issuer upon achievement thereof. The performance criteria were achieved on the date in Column 3, resulting in the vesting of the entire award.

In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 205,000 shares of common stock, which options vest according to their terms, and (ii) 1,751 shares of common stock held directly.